Botanical Ingredient

Galanthamine Safety Tips

Handling of Galanthamine should only be performed by personnel trained and familiar with the handling of potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References

• 1. [Tacrine and its derivatives in the therapy of Alzheimers disease].
  Korábe?ný J, Spilovská K, Benek O, Musílek K, Soukup O, Ku?a K.Ceska Slov Farm. 2012 Oct;61(5):210-21. Czech.
• 2. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer’s disease with monoamine oxidase inhibitors.
  Bolea I, Gella A, Unzeta M.J Neural Transm. 2012 Dec 13. [Epub ahead of print]
• 3. Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study.
  Zhang Z, Yu L, Gaudig M, Schäuble B, Richarz U.Neuropsychiatr Dis Treat. 2012;8:571-7. doi: 10.2147/NDT.S38747. Epub 2012 Dec 4.
• 4. In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.
  Remya C, Dileep KV, Tintu I, Variyar EJ, Sadasivan C.J Mol Model. 2012 Nov 16. [Epub ahead of print]
• 5. Elicitation of galanthamine production by Leucojum aestivum shoots grown in temporary immersion system.
  Schumann A, Torras-Claveria L, Berkov S, Claus D, Gerth A, Bastida J, Codina C.Biotechnol Prog. 2012 Dec 7. doi: 10.1002/btpr.1677. [Epub ahead of print]
• 6. Experimental Inhibition of Fibrillogenesis and Neurotoxicity by amyloid-beta (Aβ) and Other Disease-Related Peptides/Proteins by Plant Extracts and Herbal Compounds.
  Kumar S, Okello EJ, Harris JR.Subcell Biochem. 2012;65:295-326. doi: 10.1007/978-94-007-5416-4_13.
• 7. Endogenous acetylcholine rescues NMDA-induced long-lasting hippocampal cell damage via stimulation of muscarinic M(1) receptors: Elucidation using organic hippocampal slice cultures.
  Inada C, Thi Le X, Tsuneyama K, Fujiwara H, Miyata T, Matsumoto K.Eur J Pharmacol. 2012 Dec 7. doi:pii: S0014-2999(12)00993-4.  10.1016/j.ejphar.2012.11.061. [Epub ahead of print]
• 8. Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
  Kröger E, Berkers M, Carmichael PH, Souverein P, van Marum R, Egberts T.Am J Geriatr Pharmacother. 2012 Dec;10(6):373-80. doi: 10.1016/j.amjopharm.2012.11.002.
• 9. From Traditional European Medicine to Discovery of New Drug Candidates for the Treatment of Dementia and Alzheimer’s Disease: Acetylcholinesterase Inhibitors.
  Russo P, Frustaci A, Fini M, Cesario A.Curr Med Chem. 2012 Dec 3. [Epub ahead of print]
• 10. Investigating the binding interactions of galantamine with β-amyloid peptide.
  Rao PP, Mohamed T, Osman W.Bioorg Med Chem Lett. 2013 Jan 1;23(1):239-43. doi: 10.1016/j.bmcl.2012.10.111. Epub 2012 Nov 10.
• 11. Therapeutic interventions for aphasia initiated more than six months post stroke: a review of the evidence.
  Allen L, Mehta S, McClure JA, Teasell R.Top Stroke Rehabil. 2012 Nov-Dec;19(6):523-35. doi: 10.1310/tsr1906-523.
• 12. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model.
  Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P, Moxham T.Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165. Epub 2012 Nov 22.
• 13. Metabolic studies of the Amaryllidaceous alkaloids galantamine and lycorine based on electrochemical simulation in addition to in vivo and in vitro models.
  Jahn S, Seiwert B, Kretzing S, Abraham G, Regenthal R, Karst U.Anal Chim Acta. 2012 Dec 5;756:60-72. doi: 10.1016/j.aca.2012.10.042. Epub 2012 Nov 1.
• 14. [Viscosity changes in thickened water due to the addition of highly prescribed drugs in geriatrics].
  Garin N, de Pourcq JT, Cardona D, Martín-Venegas R, Gich I, Cardenete J, Mangues MA.Nutr Hosp. 2012 Aug;27(4):1298-303. doi: 10.3305/nh.2012.27.4.5838. Spanish.
• 15. Effects of memantine and galantamine on cognitive performance in aged rhesus macaques.
  Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E.Neurobiol Aging. 2012 Nov 15. doi:pii: S0197-4580(12)00531-3.  10.1016/j.neurobiolaging.2012.10.020. [Epub ahead of print]
• 16. Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice.
  Busquet P, Capurro V, Cavalli A, Piomelli D, Reggiani A, Bertorelli R.J Pharmacol Sci. 2012 Dec 18;120(4):305-9. Epub 2012 Nov 13.
• 17. Wild argentinian amaryllidaceae, a new renewable source of the acetylcholinesterase inhibitor galanthamine and  other alkaloids.
  Ortiz JE, Berkov S, Pigni NB, Theoduloz C, Roitman G, Tapia A, Bastida J, Feresin GE.Molecules. 2012 Nov 13;17(11):13473-82. doi: 10.3390/molecules171113473.
• 18. Dopamine modulates processing speed in the human mesolimbic system.
  Eckart C, Bunzeck N.Neuroimage. 2012 Nov 8;66C:293-300. doi: 10.1016/j.neuroimage.2012.11.001. [Epub ahead of print]
• 19. [New approach to gait disorders therapy in late stages of Parkinson’s disease].
  Litvinenko IV, Khalimov RR, Trufanov AG, Krasakov IV, Kha?mov DA.Adv Gerontol. 2012;25(2):267-74. Russian.
• 20. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort.
  Wattmo C, Wallin AK, Minthon L.BMC Neurol. 2012 Nov 5;12(1):134. [Epub ahead of print]

Details